Correction to: J ImmunoTher Cancer
https://doi.org/10.1186/s40425-019-0689-7
Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”
should be replaced with
“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”
Reference
Florou, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213. https://doi.org/10.1186/s40425-019-0689-7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Florou, V., Rosenberg, A.E., Wieder, E. et al. Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. j. immunotherapy cancer 7, 285 (2019). https://doi.org/10.1186/s40425-019-0792-9
Published:
DOI: https://doi.org/10.1186/s40425-019-0792-9